Medicare AdvantageCoverageMedium impact
MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)
Independence Blue Cross·Orthopedics, Rheumatology, Pain Management +1 more·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.097a for Triamcinolone Acetonide ER Injectable (Zilretta®) has been reissued with updates effective April 1, 2026. This is a fresh policy update affecting coverage and billing requirements for this extended-release injectable medication used primarily for osteoarthritis pain management.
Action Required
Before April 1, 2026: Billing team must review updated policy MA08.097a for Zilretta® injections and verify current coverage criteria, prior authorization requirements, and billing guidelines for Medicare Advantage plans. Update billing procedures and staff training materials accordingly to ensure compliant claims submission.